Investor Centre

Latest results

Half Year Financial
Report to 31 Dec 2021

View Results Centre

2021 Annual General Meeting

Read more

Clinical Trials Science Forum - Recording available

ACW held its Clinical Trials Science Forum via webcast on 3 August. Our aim is to provide a deeper understanding of our company while limiting the science-speak and jargon.

View Announcement

View webcast recording

ASX Announcements

Analyst Reports

  • 12 May 2022

    Edison Healthcare Insight: May 2022

    Analyst: Soo Romanoff
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 9 May 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 14 Apr 2022

    Edison Healthcare Insight: April 2022

    Analyst: Jonas Peculias
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 11 April 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 17 Mar 2022

    Edison Healthcare Insight: March 2022

    Analyst: Jonas Peculias
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 14 March 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 10 Feb 2022

    Edison Healthcare Insight: February 2022

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 February 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Right to Receive Documents

Find out more

Frequently Asked Questions

When did the Company become a publicly listed company?

The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine from Edinburgh University, a company focused on the development of brain penetrant 11β-HSD1 enzyme inhibitors for the treatment of cognitive impairment.  The lead drug in development by Corticrine was Xanamem. Corticrine received A$25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 (Xanamem) in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.

What are the Company’s head office contact details?

Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000

Who manages the share register?

The share registry is managed by Automic Pty Ltd. To login and access your holding information, please go to: https://investor.automic.com.au

How can I check my shareholdings?

Shareholders can check their shareholdings by logging into  the Automic investor portal https://investor.automic.com.au

If you have any queries in relation to your shareholding, please contact Automic by  telephone on 1300 288 664 (within Australia) or +61 2 9698 5414 (international) or by email at hello@automicgroup.com.au.

How can I buy and sell shares in Actinogen Medical?

All company shares are traded on the Australian Securities Exchange (ASX) and can be bought or sold through a licensed stockbroker. The process of buying or selling shares is explained on the ASX website; please go to
https://www.asx.com.au/products/shares/buying-selling-shares.htm

I am an overseas investor – how can I buy and sell shares?

Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.

How can I obtain a copy of the Annual Report?

All annual reports are available on our website through this link.

How can I follow the Company’s share price activity?

Current share prices are available on the ASX website www.asx.com.au and can be searched using the Company’s ASX ticker symbol: ACW. A 20-minute delayed share price graph can also be found in our Investor Centre.

What is the ASX ticker code?
Where can I find the latest financial information?

The latest financial reports can be found in our Results Centre.

What is the Company’s financial year end?

The Company’s end of financial year is the 30th of June

When will the Annual General Meeting be held?

As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end.  Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.

Who are the auditors?

The Company’s auditors are Ernst and Young

Where can I find the Corporate Governance Statement and corporate governance policies?

Our Corporate Governance Statement can be found on our website at: https://actinogen.com.au/investor-centre/#corporate-governance

This section includes downloadable PDFs of our Board and Committee Charters, the Constitution, Anti-Bribery and Corruption Policy, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Policy, Risk Management and Internal Compliance and Control, Securities Trading Policy, and Shareholders Communication Policy.

Does Actinogen have a dividend policy?

The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses it against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.

Corporate Governance

Find out more

Investor Contacts

Actinogen Medical Ltd (ACN 086 778 476) is listed on the Australian Securities Exchange (ASX) with the code ACW.

Retail shareholder queries should be directed to Actinogen Medical’s share registrars, Automic Pty Ltd.

Address:

Level 5, 126 Phillip Street
Sydney NSW 2000
Australia

GPO Box 5193
Sydney NSW 2001
Australia

Phone:

+61 1300 288 664 (within Australia)
+61 (0)2 9698 5414 (Overseas)

Email:

hello@automicgroup.com.au

Web:

www.automicgroup.com.au


Back
to top